Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study of ANX005 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females 18 years and older~* Females must be postmenopausal, surgically sterilized, or willing and able to use 2 methods of contraception throughout the study and for 1 month after the final study visit~* Willing and able to undergo vaccination if not vaccinated recently~Exclusion Criteria:~* History of any autoimmune disease, meningitis, septicemia or pneumonia~* History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or acute renal failure~* Known genetic deficiencies of the complement cascade system~* History of conditions whose symptoms and effects could alter protein catabolism or IgG utilization, e.g. protein-losing enteropathies or nephrotic syndrome~* Body weight less than 50 kg or greater than 100 kg~* Hypersensitivity or allergic reactions to any excipients in the ANX005 drug product~* (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at screening~* (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including IVIg or any of the excipients in IVIg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ANX005 Monotherapy (Type: EXPERIMENTAL): ANX005 intravenous infusion
- ANX005 and IVIg Combination Therapy (Type: EXPERIMENTAL): ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).